Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The p53 roles have been largely described; among them, cell proliferation and apoptosis control are some of the best studied and understood. Interestingly, the mutations on the six hotspot sites within the region that encodes the DNA-binding domain of p53 give rise to other very different variants. The particular behavior of these variants led to consider p53 mutants as separate oncogene entities; that is, they do not retain wild type functions but acquire new ones, namely Gain-of-function p53 mutants. Furthermore, recent studies have revealed how p53 mutants regulate gene expression and exert oncogenic effects by unbalancing specific microRNAs (miRNAs) levels that provoke epithelial-mesenchymal transition, chemoresistance, and cell survival, among others. In this review, we discuss recent evidence of the crosstalk between miRNAs and mutants of p53, as well as the consequent cellular processes dysregulated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The TP53 gene predominantly undergoes missense mutations, resulting in the synthesis of a mutant p53 protein that retains its full length. This is in contrast to most tumor suppressor genes, which are usually inactivated by biallelic deletion or truncation mutations [5].”
From The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies (2025) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
Mauthe, M., Orhon, I., Rocchi, C., Zhou, X., Luhr, M., Hijlkema, K.-J., Coppes, R. P., Engedal, N., Mari, M., & Reggiori, F. (2018) · Autophagy · doi:10.1080/15548627.2018.1474314 · Cited by 2,122
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“Besides, the mutant p53 protein can, in many cases, lose its functions and may exert a dominant negative regulation on any remaining p53 wt (Petitjean et al., 2007).”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“The mutations in the gene TP53 are mainly missense, resulting in the production of a full-length mutant p53 protein, unlike most tumor suppressor genes inactivated through biallelic deletion or truncation mutations (Li et al., 2014a; Muller and Vousden, 2014).”
BackgroundCancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., Yu, Y., Chow, A., O’Connor, S. T. F., Chin, A. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.007 · Cited by 1,476
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 1×
“, 2014a); these functions are entirely independent of p53 wt function (Strano et al., 2007; Brosh and Rotter, 2009).”
BackgroundZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518 · cited 5×
“…mRNA can be concurrently regulated by multiple miRNAs, and an estimated 60% of the human genome is regulated by miRNAs (Hermeking, 2012). miRNAs are regulators of numerous cellular processes, including proliferation, differentiation, and apoptosis (Hainaut and Hollstein, 2000; Hermeking, 2012).”
BackgroundInfluentialZhu, X., Shen, H., Yin, X., Yang, M., Wei, H., Chen, Q., Feng, F., Liu, Y., Xu, W., & Li, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1095-1 · Cited by 374
Research works printed but not linked: 99
- Abdelmohsen, 2010, miR-519 Suppresses Tumor Growth by Reducing HuR Levels, Cell Cycle, 9, 1354, 10.4161/cc.9.7.11164 · DOI · Paper page
- Ahn, 1999, Down-regulation of the stathmin/Op18 and FKBP25 Genes Following P53 Induction, Oncogene, 18, 5954, 10.1038/sj.onc.1202986 · DOI
- Bornachea, 2012, EMT and Induction of miR-21 Mediate Metastasis Development in Trp53-Deficient Tumours, Sci. Rep., 2, 434, 10.1038/srep00434 · DOI
- Boyerinas, 2010, The Role of Let-7 in Cell Differentiation and Cancer, Endocr. Relat. Cancer, 17, F19, 10.1677/erc-09-0184 · DOI · Paper page
- Bullock, 2001, Rescuing the Function of Mutant P53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Buonfiglioli, 2019, let-7 MicroRNAs Regulate Microglial Function and Suppress Glioma Growth through Toll-like Receptor 7, Cel Rep., 29, 3460, 10.1016/j.celrep.2019.11.029 · DOI · Paper page
- Calin, 2006, MicroRNA Signatures in Human Cancers, Nat. Rev. Cancer, 6, 857, 10.1038/nrc1997 · DOI · Paper page
- Capaci, 2020, Mutant P53 Induces Golgi Tubulo-Vesiculation Driving a Prometastatic Secretome, Nat. Commun., 11, 3945, 10.1038/s41467-020-17596-5 · DOI · Paper page
- Chang, 2013, Acetylation of P53 Stimulates miRNA Processing and Determines Cell Survival Following Genotoxic Stress, Embo j, 32, 3192, 10.1038/emboj.2013.242 · DOI
- Chirshev, 2019, Let-7 as Biomarker, Prognostic Indicator, and Therapy for Precision Medicine in Cancer, Clin. Transl Med., 8, 24, 10.1186/s40169-019-0240-y · DOI · Paper page
- Cimmino, 2005, miR-15 and miR-16 Induce Apoptosis by Targeting BCL2, Proc. Natl. Acad. Sci., 102, 13944, 10.1073/pnas.0506654102 · DOI · Paper page
- Citron, 2020, Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer, Cancer Res., 80, 1064, 10.1158/0008-5472.can-19-1793 · DOI · Paper page
- Croce, 2009, Causes and Consequences of microRNA Dysregulation in Cancer, Nat. Rev. Genet., 10, 704, 10.1038/nrg2634 · DOI · Paper page
- Denli, 2004, Processing of Primary microRNAs by the Microprocessor Complex, Nature, 432, 231, 10.1038/nature03049 · DOI · Paper page
- Di Agostino, 2020, The Impact of Mutant P53 in the Non-coding RNA World, Biomolecules, 10, 472, 10.3390/biom10030472 · DOI
- Dong, 2013, Mutant P53 Gain-Of-Function Induces Epithelial-Mesenchymal Transition through Modulation of the miR-130b-ZEB1 axis, Oncogene, 32, 3286, 10.1038/onc.2012.334 · DOI · Paper page
- Donzelli, 2012, MicroRNA-128-2 Targets the Transcriptional Repressor E2F5 Enhancing Mutant P53 Gain of Function, Cell Death Differ, 19, 1038, 10.1038/cdd.2011.190 · DOI
- Donzelli, 2014, microRNAs: Short Non-coding Bullets of Gain of Function Mutant P53 Proteins, Oncoscience, 1, 427, 10.18632/oncoscience.52 · DOI
- Du, 2019, miR-517a Is Up-Regulated in Glioma and Promotes Glioma Tumorigenesis In Vitro and In Vivo, Biosci. Rep., 39, 10.1042/BSR20181196 · DOI
- Fort, 2018, An Integrated View of the Role of miR-130b/301b miRNA Cluster in Prostate Cancer, Exp. Hematol. Oncol., 7, 10, 10.1186/s40164-018-0102-0 · DOI
- Ganci, 2013, Expression of TP53 Mutation-Associated microRNAs Predicts Clinical Outcome in Head and Neck Squamous Cell Carcinoma Patients, Ann. Oncol., 24, 3082, 10.1093/annonc/mdt380 · DOI
- Gao, 2020, Exosomal Transfer of Macrophage-Derived miR-223 Confers Doxorubicin Resistance in Gastric Cancer, Ott, 12169, 10.2147/ott.s283542 · DOI
- Gao, 2020, MicroRNA-105 Plays an Independent Prognostic Role in Esophageal Cancer and Acts as an Oncogene, Cbm, 27, 173, 10.3233/cbm-190736 · doi:10.3233/cbm-190736
- Garibaldi, 2016, Mutant P53 Inhibits miRNA Biogenesis by Interfering with the Microprocessor Complex, Oncogene, 35, 3760, 10.1038/onc.2016.51 · DOI
- Garibaldi, 2016, Mutant P53 Inhibits miRNA Biogenesis by Interfering with the Microprocessor Complex, Oncogene, 35, 3760, 10.1038/onc.2016.51 · DOI
- Gasparini, 2014, Protective Role of miR-155 in Breast Cancer through RAD51 Targeting Impairs Homologous Recombination after Irradiation, Proc. Natl. Acad. Sci., 111, 4536, 10.1073/pnas.1402604111 · DOI · Paper page
- Gu, 2016, miR-27a Attenuates Adipogenesis and Promotes Osteogenesis in Steroid-Induced Rat BMSCs by Targeting PPARγ and GREM1, Sci. Rep., 6, 38491, 10.1038/srep38491 · DOI
- Gurtner, 2016, Dysregulation of microRNA Biogenesis in Cancer: the Impact of Mutant P53 on Drosha Complex Activity, J. Exp. Clin. Cancer Res., 35, 45, 10.1186/s13046-016-0319-x · DOI
- Ha, 2014, Regulation of microRNA Biogenesis, Nat. Rev. Mol. Cel Biol, 15, 509, 10.1038/nrm3838 · DOI · Paper page
- Hainaut, 2000, p53 and Human Cancer: the First Ten Thousand Mutations, Adv. Cancer Res., 77, 81, 10.1016/s0065-230x(08)60785-x · DOI · Paper page
- Halcrow, 2021, Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine, Front. Cel Dev. Biol., 9, 627639, 10.3389/fcell.2021.627639 · DOI
- Hertel, 2012, Evolution of the Let-7 microRNA Family, RNA Biol., 9, 231, 10.4161/rna.18974 · DOI · Paper page
- Hirono, 2019, MicroRNA-130b Functions as an oncomiRNA in Non-small Cell Lung Cancer by Targeting Tissue Inhibitor of Metalloproteinase-2, Sci. Rep., 9, 6956, 10.1038/s41598-019-43355-8 · DOI
- Hu, 2018, MiR-27b Impairs Adipocyte Differentiation of Human Adipose Tissue-Derived Mesenchymal Stem Cells by Targeting LPL, Cell Physiol Biochem, 47, 545, 10.1159/000489988 · doi:10.1159/000489988
- Hu, 2019, Aberrant Expression and Mechanism of miR-130b-3p/phosphatase and Tensin Homolog in Nephroblastoma in Children, Exp. Ther. Med., 18, 1021, 10.3892/etm.2019.7643 · DOI
- Huang, 2015, miR-128 Как Ключевой Регулятор онкогенности, Молекул. биол., 49, 46, 10.7868/s0026898415010061 · DOI
- Jansson, 2012, MicroRNA and Cancer, Mol. Oncol., 6, 590, 10.1016/j.molonc.2012.09.006 · DOI · Paper page
- Jiang, 2015, Mutant P53 Induces EZH2 Expression and Promotes Epithelial-Mesenchymal Transition by Disrupting P68-Drosha Complex Assembly and Attenuating miR-26a Processing, Oncotarget, 6, 44660, 10.18632/oncotarget.6350 · DOI
- Jin, 2019, Up-regulation of miRNA-105 Inhibits the Progression of Gastric Carcinoma by Directly Targeting SOX9, Eur. Rev. Med. Pharmacol. Sci., 23, 3779, 10.26355/eurrev_201905_17804 · doi:10.26355/eurrev_201905_17804
- Jin, 2016, FXR1 Is Elevated in Colorectal Cancer and Acts as an Oncogene, Tumor Biol., 37, 2683, 10.1007/s13277-015-4068-9 · DOI
- Jones, 2012, MicroRNAs, Wild-type and Mutant P53: More Questions Than Answers, RNA Biol., 9, 781, 10.4161/rna.20146 · DOI · Paper page
- Kim, 2010, miR-27a Is a Negative Regulator of Adipocyte Differentiation via Suppressing PPARγ Expression, Biochem. Biophysical Res. Commun., 392, 323, 10.1016/j.bbrc.2010.01.012 · DOI · Paper page
- Kumar, 2008, CBFA2T3-ZNF652 Corepressor Complex Regulates Transcription of the E-Box Gene HEB, J. Biol. Chem., 283, 19026, 10.1074/jbc.m709136200 · DOI
- Kumar, 2006, ZNF652, a Novel Zinc finger Protein, Interacts with the Putative Breast Tumor Suppressor CBFA2T3 to Repress Transcription, Mol. Cancer Res., 4, 655, 10.1158/1541-7786.mcr-05-0249 · DOI
- Landi, 2013, Irreversible EGFR-TKIs: Dreaming Perfection, Transl Lung Cancer Res., 2, 40, 10.3978/j.issn.2218-6751.2012.12.05 · DOI
- Li, 2014, Deregulation of miR-128 in Ovarian Cancer Promotes Cisplatin Resistance, Int. J. Gynecol. Cancer, 24, 1381, 10.1097/igc.0000000000000252 · DOI
- Li, 2013, miR-128 and its Target Genes in Tumorigenesis and Metastasis, Exp. Cel Res., 319, 3059, 10.1016/j.yexcr.2013.07.031 · DOI · Paper page
- Li, 2014, Mutant P53 Exerts Oncogenic Effects through microRNAs and Their Target Gene Networks, FEBS Lett., 588, 2610, 10.1016/j.febslet.2014.03.054 · DOI
- Li, 2020, Bmi-1-induced miR-27a and miR-155 Promote Tumor Metastasis and Chemoresistance by Targeting RKIP in Gastric Cancer, Mol. Cancer, 19, 109, 10.1186/s12943-020-01229-y · DOI
- Lian, 2018, miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis, Cel Physiol Biochem, 49, 2151, 10.1159/000493818 · DOI · Paper page
- Liu, 2018, MicroRNA-155 Acts as a Tumor Suppressor in Colorectal Cancer by Targeting CTHRC1 In Vitro, Oncol. Lett., 15, 5561, 10.3892/ol.2018.8069 · DOI
- Liu, 2013, Down-regulation of miR-517a and miR-517c Promotes Proliferation of Hepatocellular Carcinoma Cells via Targeting Pyk2, Cancer Lett., 329, 164, 10.1016/j.canlet.2012.10.027 · DOI
- Liu, 2017, Exosomes Containing miR-21 Transfer the Characteristic of Cisplatin Resistance by Targeting PTEN and PDCD4 in Oral Squamous Cell Carcinoma, Acta Biochim. Biophys. Sin (Shanghai), 49, 808, 10.1093/abbs/gmx078 · DOI · Paper page
- Liu, 2019, Exosome-transmitted miR-128-3p Increase Chemosensitivity of Oxaliplatin-Resistant Colorectal Cancer, Mol. Cancer, 18, 43, 10.1186/s12943-019-0981-7 · DOI · Paper page
- Liu, 2020, Nanocomplexes Loaded with miR-128-3p for Enhancing Chemotherapy Effect of Colorectal Cancer through Dual-Targeting Silence the Activity of PI3K/AKT and MEK/ERK Pathway, Drug Deliv., 27, 323, 10.1080/10717544.2020.1716882 · DOI
- Liu, 2021, MicroRNA223induced Inhibition of the FBXW7 Gene Affects the Proliferation and Apoptosis of Colorectal Cancer Cells via the Notch and Akt/mTOR Pathways, Mol. Med. Rep., 23, 154, 10.3892/mmr.2020.11793 · DOI
- Ma, 2016, miR-517a Is an Independent Prognostic Marker and Contributes to Cell Migration and Invasion in Human Colorectal Cancer, Oncol. Lett., 11, 2583, 10.3892/ol.2016.4269 · DOI
- Maleki, 2021, The Role of Extracellular Vesicles in Mediating Resistance to Anticancer Therapies, Int. J. Mol. Sci., 22, 4166, 10.3390/ijms22084166 · DOI
- Masciarelli, 2014, Gain-of-function Mutant P53 Downregulates miR-223 Contributing to Chemoresistance of Cultured Tumor Cells, Oncogene, 33, 1601, 10.1038/onc.2013.106 · DOI · Paper page
- Mashima, 2015, Physiological Roles of miR-155, Immunology, 145, 323, 10.1111/imm.12468 · DOI · Paper page
- Masood, 2019, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: Focus on Afatinib, Semin. Oncol., 46, 271, 10.1053/j.seminoncol.2019.08.004 · DOI
- Mello, 2013, Not all P53 Gain-Of-Function Mutants Are Created Equal, Cel Death Differ, 20, 855, 10.1038/cdd.2013.53 · DOI · Paper page
- Miura, 2010, Identification of Pregnancy-Associated microRNAs in Maternal Plasma, Clin. Chem., 56, 1767, 10.1373/clinchem.2010.147660 · DOI · Paper page
- Mizuno, 2018, The Molecular Basis and Therapeutic Potential of Let-7 MicroRNAs against Colorectal Cancer, Can. J. Gastroenterol. Hepatol., 2018, 5769591, 10.1155/2018/5769591 · DOI · Paper page
- Muller, 2014, Mutant P53 Regulates Dicer through P63-dependent and -independent Mechanisms to Promote an Invasive Phenotype, J. Biol. Chem., 289, 122, 10.1074/jbc.m113.502138 · DOI · Paper page
- Neilsen, 2013, Mutant P53 Drives Invasion in Breast Tumors through Up-Regulation of miR-155, Oncogene, 32, 2992, 10.1038/onc.2012.305 · DOI · Paper page
- O'Brien, 2018, Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation, Front. Endocrinol., 9, 402, 10.3389/fendo.2018.00402 · DOI · Paper page
- Phadke, 2011, In vivoSafety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein, DNA Cel Biol., 30, 715, 10.1089/dna.2011.1240 · DOI
- Rana, 2008, Stathmin 1: a Novel Therapeutic Target for Anticancer Activity, Expert Rev. Anticancer Ther., 8, 1461, 10.1586/14737140.8.9.1461 · DOI · Paper page
- Russo, 2017, Third Generation EGFR TKIs in EGFR-Mutated NSCLC: Where Are We Now and where Are We Going, Crit. Rev. Oncology/Hematology, 117, 38, 10.1016/j.critrevonc.2017.07.003 · DOI
- Saito, 2015, microRNA-34a as a Therapeutic Agent against Human Cancer, Jcm, 4, 1951, 10.3390/jcm4111951 · DOI
- Shang, 2019, MiR-105 Inhibits Gastric Cancer Cells Metastasis, Epithelial-Mesenchymal Transition by Targeting SOX9, Eur. Rev. Med. Pharmacol. Sci., 23, 6160, 10.26355/eurrev_201907_18429 · doi:10.26355/eurrev_201907_18429
- She, 2014, miR-128 and miR-149 Enhance the Chemosensitivity of Temozolomide by Rap1B-Mediated Cytoskeletal Remodeling in Glioblastoma, Oncol. Rep., 32, 957, 10.3892/or.2014.3318 · DOI · Paper page
- Strano, 2007, Mutant P53 Proteins: between Loss and Gain of Function, Head Neck, 29, 488, 10.1002/hed.20531 · DOI · Paper page
- Su, 2019, miR-27a-3p Regulates Proliferation and Apoptosis of colon Cancer Cells by Potentially Targeting BTG1, Oncol. Lett., 18, 2825, 10.3892/ol.2019.10629 · DOI
- Subramanian, 2015, A Mutant p53/let-7i-axis-regulated Gene Network Drives Cell Migration, Invasion and Metastasis, Oncogene, 34, 1094, 10.1038/onc.2014.46 · DOI · Paper page
- Sun, 2008, Proline-rich Tyrosine Kinase 2 (Pyk2) Promotes Proliferation and Invasiveness of Hepatocellular Carcinoma Cells through C-Src/ERK Activation, Carcinogenesis, 29, 2096, 10.1093/carcin/bgn203 · DOI
- Sun, 2013, Diverse Functions of miR-125 Family in Different Cell Contexts, J. Hematol. Oncol., 6, 6, 10.1186/1756-8722-6-6 · DOI · Paper page
- Sun, 2019, miR-27a Regulates Vascular Remodeling by Targeting Endothelial Cells' Apoptosis and Interaction with Vascular Smooth Muscle Cells in Aortic Dissection, Theranostics, 9, 7961, 10.7150/thno.35737 · DOI
- Suzuki, 2009, Modulation of microRNA Processing by P53, Nature, 460, 529, 10.1038/nature08199 · DOI · Paper page
- Svoronos, 2016, OncomiR or Tumor Suppressor? the Duplicity of MicroRNAs in Cancer, Cancer Res., 76, 3666, 10.1158/0008-5472.can-16-0359 · DOI · Paper page
- Tang, 2014, miR-27a Regulates Endothelial Differentiation of Breast Cancer Stem like Cells, Oncogene, 33, 2629, 10.1038/onc.2013.214 · DOI
- Tie, 2010, MiR-218 Inhibits Invasion and Metastasis of Gastric Cancer by Targeting the Robo1 Receptor, Plos Genet., 6, e1000879, 10.1371/journal.pgen.1000879 · DOI · Paper page
- Tu, 2013, MicroRNA-218 Inhibits Glioma Invasion, Migration, Proliferation, and Cancer Stem-like Cell Self-Renewal by Targeting the Polycomb Group Gene Bmi1, Cancer Res., 73, 6046, 10.1158/0008-5472.can-13-0358 · DOI · Paper page
- Valenti, 2019, The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas, Cancers (Basel), 11, 1347, 10.3390/cancers11091347 · DOI
- Vasudevan, 2007, Switching from Repression to Activation: microRNAs Can Up-Regulate Translation, Science, 318, 1931, 10.1126/science.1149460 · DOI · Paper page
- Vigorito, 2013, miR-155: an Ancient Regulator of the Immune System, Immunol. Rev., 253, 146, 10.1111/imr.12057 · DOI · Paper page
- Walerych, 2016, Proteasome Machinery Is Instrumental in a Common Gain-Of-Function Program of the P53 Missense Mutants in Cancer, Nat. Cel Biol, 18, 897, 10.1038/ncb3380 · DOI · Paper page
- Wang, 2020, MiR-223 Regulates Autophagy Associated with Cisplatin Resistance by Targeting FBXW7 in Human Non-small Cell Lung Cancer, Cancer Cel Int, 20, 258, 10.1186/s12935-020-01284-x · DOI
- Wang, 2015, Correlation of Increased Expression of MicroRNA-155 in Bladder Cancer and Prognosis, Lab. Med., 46, 118, 10.1309/lmwr9cea2k2xvsox · DOI
- Wang, 2013, Mutant P53-R273h Gains New Function in Sustained Activation of EGFR Signaling via Suppressing miR-27a Expression, Cell Death Dis, 4, e574, 10.1038/cddis.2013.97 · DOI
- Xu, 2013, miR-24-3p and miR-27a-3p Promote Cell Proliferation in Glioma Cells via Cooperative Regulation of MXI1, Int. J. Oncol., 42, 757, 10.3892/ijo.2012.1742 · DOI · Paper page
- Yang, 2020, Silencing of microRNA-517a Induces Oxidative Stress Injury in Melanoma Cells via Inactivation of the JNK Signaling Pathway by Upregulating CDKN1C, Cancer Cel Int, 20, 32, 10.1186/s12935-019-1064-y · DOI
- Ye, 2018, Role of miR-223 in the Pathophysiology of Liver Diseases, Exp. Mol. Med., 50, 128, 10.1038/s12276-018-0153-7 · DOI · Paper page
- Yoshitomi, 2011, Restoration of miR-517a Expression Induces Cell Apoptosis in Bladder Cancer Cell Lines, Oncol. Rep., 25, 1661, 10.3892/or.2011.1253 · doi:10.3892/or.2011.1253
- You, 2016, MiR-27a Is Essential for the Shift from Osteogenic Differentiation to Adipogenic Differentiation of Mesenchymal Stem Cells in Postmenopausal Osteoporosis, Cel Physiol Biochem, 39, 253, 10.1159/000445621 · DOI
- Zhang, 2016, Gain-of-function miRNA Signature by Mutant P53 Associates with Poor Cancer Outcome, Oncotarget, 7, 11056, 10.18632/oncotarget.7090 · DOI
- Zhao, 2013, MiR-130b Is a Prognostic Marker and Inhibits Cell Proliferation and Invasion in Pancreatic Cancer through Targeting STAT3, PLoS One, 8, e73803, 10.1371/journal.pone.0073803 · DOI
- Zhou, 2018, MicroRNA-223 Suppresses the Canonical NF-Κb Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation, Cel Rep., 22, 1810, 10.1016/j.celrep.2018.01.058 · DOI · Paper page
Cited by
Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B. (2025) · PLOS One · doi:10.1371/journal.pone.0307859 · Cited by 4
Metadata
- Authors
- Madrigal, T., Hernández-Monge, J., Herrera, L. A., González-De la Rosa, C. H., Domínguez-Gómez, G., Candelaria, M., Luna-Maldonado, F., Calderón González, K. G., & Díaz-Chávez, J.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2021-12-06
- Volume
- 9
- ISSN
- 2296-634X
- Cited by
- 17
- References
- 8
- Funders
- Consejo Nacional de Ciencia y Tecnología (168896 261875)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer. https://app.cochat.ai/papers/10.3389/fcell.2021.695723
- The paper
- Madrigal, T., Hernández-Monge, J., Herrera, L. A., González-De la Rosa, C. H., Domínguez-Gómez, G., Candelaria, M., Luna-Maldonado, F., Calderón González, K. G., & Díaz-Chávez, J. (2021). Regulation of miRNAs Expression by Mutant p53 Gain of Function in Cancer. Frontiers in Cell and Developmental Biology. https://doi.org/10.3389/fcell.2021.695723
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.